Biotech Giant Beats Views, Narrows EPS Guidance

Gilead stock edged lower late Thursday after the biotech company reported adjusted earnings of $1.87 per share on $6.217 billion in second-quarter sales.


On average, analysts polled by FactSet expected Gilead Sciences (GILD) to earn $1.74 a share on $6.08 billion in sales.

In the year-earlier period, Gilead earned $1.11 per share and reported $5.14 billion in sales.

For the year, Gilead narrowed its per-share earnings range to $6.90-$7.25 from $6.75-7.45, with the midpoint slightly lower. Analysts called for adjusted profit of $7.11 per share and $24.67 billion in sales.

In after-hours trading on the stock market today, Gilead stock fell 0.5%. GILD stock is forming a flat base with a buy point at 70.21, according to

Gilead stock narrowly topped that entry during the regular session before pulling back to close down 0.3% 69.83.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Why Merck Stock Might Sacrifice Its Breakout Despite Beating Sales Forecasts

Annovis Bio Stock Crashes After Much-Hyped Alzheimer’s Drug Flops In Midstage Test

IBD’s Leaderboard Is Turning 10! Help Us Celebrate

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button